Tomoyuki Igawa, Ph.D. - CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
Previously, antibody engineering was mainly applied to improve the properties of a parent antibody by methods such as humanization, affinity maturation, stability engineering and half-life extension. Recent advances in antibody engineering have enabled us to conceive and realize novel antibody drug concepts. This presentation describes how antibody engineering technologies can drive the discovery of innovative antibody drugs.